Database release
In this release, we add two recent precision oncology approvals from the FDA regarding ER signaling inhibition in two cancer types.
Posts are organized into categories for ease of navigation:
In this release, we add two recent precision oncology approvals from the FDA regarding ER signaling inhibition in two cancer types.
In this release, we add two recent precision oncology approvals from the FDA.
In this release, we have removed neoantigen burden as a cataloged feature type and combined Silencing with Knockdown feature types. We additionally expanded upon fields required for each feature type within our S.O.P.
This release utilizes the v.2021-02-04 release of the underlying MOAlmanac database.